Amarin Corp Plc (AMRN)

[dogn]

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients
An adjuvant anti-inflammatory might offer more protection than additional lipid-lowering, a meta-analysis hints.

MARCH 14, 2023

https://www.tctmd.com/news/crp-more-predictive-future-events-ldl-statin-treated-patients

More than half of the trial participants had hsCRP ≥ 2 mg/L. This criterion alone put them at greater risk of MACE, CV death, and all-cause death, irrespective of whether they had an LDL cholesterol ≥ 70 mg/dL.

“While these data must not be construed to diminish the proven and crucial role of adjunctive lipid-lowering for those with persistent or refractory health hypercholesterolemia, our data do suggest that targeting of LDL alone is unlikely to completely reduce atherosclerotic risk and that inflammatory pathways have yet to be fully exploited to really address this issue,” Ridker concluded.

“I would argue, as I have for quite a few years, [that] we all should be measuring CRP,” Ridker concurred. “We measure LDL so we know what we’re doing. We measure blood pressure so we know what we’re doing. If you’re not measuring CRP, you have no idea that your patient even has this problem, and clearly in these 32,000 patients this was rather important.”
…
———————
Ridker doesn’t mention Vascepa/IPE as a treatment option although it is the drug used in one of three trials in meta-analysis! He was also lead author of the biomarkers analysis that Bhatt & others said reviewers/editors blocked inclusion of important additional analysis from. Perhaps the recently presented favorable hsCRP data is part of the blocked added analysis? Seems Ridker has a bias against IPE.

dogn